Lymphotoxin α stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts

Cytokine

Volumn 53, Issue 2, 2011, Pages 207-214

  Calmon Hamaty, Flavia ^a   Combe, Bernard ^a,b,c   Hahne, Michael ^a,c   Morel, Jacques ^a,b,c  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

Inflammatory cytokines; Lymphotoxin ; Proliferation; Rheumatoid arthritis; Synovial fibroblasts

Indexed keywords

ETANERCEPT; HERPESVIRUS ENTRY MEDIATOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; FIBROBLAST LIKE SYNOVIOCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ARTHRITIS, RHEUMATOID; CELL NUCLEUS; CELL PROLIFERATION; CYTOKINES; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION MEDIATORS; LYMPHOTOXIN-ALPHA; MATRIX METALLOPROTEINASE 3; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SYNOVIAL FLUID;

EID: 78651083662     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.10.010     Document Type: Article

References (34)

1. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423(6937):356-361.
2. Pope R.M. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2002, 2(7):527-535.
3. Arend W.P., Dayer J.M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990, 33(3):305-315.
4. Ware C.F. Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 2005, 23:787-819.
5. Deleuran B.W., Chu C.Q., Field M., Brennan F.M., Mitchell T., Feldmann M., et al. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum 1992, 35(10):1170-1178.
6. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991, 10(13):4025-4031.
7. Thorbecke G.J., Shah R., Leu C.H., Kuruvilla A.P., Hardison A.M., Palladino M.A. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992, 89(16):7375-7379.
8. Williams R.O., Feldmann M., Maini R.N. Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha. Ann Rheum Dis 2000, 59(1):i75-i80.
9. Schneider K., Potter K.G., Ware C.F. Lymphotoxin and LIGHT signaling pathways and target genes. Immunol Rev 2004, 202:49-66.
10. Medvedev A.E., Espevik T., Ranges G., Sundan A. Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects. J Biol Chem 1996, 271(16):9778-9784.
11. Mauri D.N., Ebner R., Montgomery R.I., Kochel K.D., Cheung T.C., Yu G.L., et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998, 8(1):21-30.
12. Körner H., Sedgwick J.D. Tumour necrosis factor and lymphotoxin: molecular aspects and role in tissue-specific autoimmunity. Immunol Cell Biol 1996, 74(5):465-472.
13. Tumanov A.V., Grivennikov S.I., Shakhov A.N., Rybtsov S.A., Koroleva E.P., Takeda J., et al. Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunol Rev 2003, 195:106-116.
14. Robak T., Gladalska A., Stepien H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998, 9(2):145-154.
15. Buch M.H., Conaghan P.G., Quinn M.A., Bingham S.J., Veale D., Emery P. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?. Ann Rheum Dis 2004, 63(10):1344-1346.
16. Chiang E.Y., Kolumam G.A., Yu X., Francesco M., Ivelja S., Peng I., et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009, 15(7):766-773.
17. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
18. Morel J., Audo R., Hahne M., Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005, 280:15709-15718.
19. Morel J.C., Park C.C., Zhu K., Kumar P., Ruth J.H., Koch A.E. Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J Biol Chem 2002, 277:34679-34691.
20. Franke T.F., Hornik C.P., Segev L., Shostak G.A., Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22:8983-8998.
21. Reddy S.A., Huang J.H., Liao W.S. Phosphatidylinositol 3-kinase as a mediator of TNF-induced NF-κB activation. J Immunol 2000, 164(3):1355-1363.
22. Firestein G.S., Manning A.M. Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 1999, 42(4):609-621.
23. May M.J., Ghosh S. Signal transduction through NF-κB. Immunol Today 1998, 19(2):80-88.
24. Jung H.W., La S.J., Kim J.Y., Heo S.K., Kim J.Y., Wang S., et al. High levels of soluble herpes virus entry mediator in sera of patients with allergic and autoimmune diseases. Exp Mol Med 2003, 35(6):501-508.
25. Olsen N.J., Stein C.M. New drugs for rheumatoid arthritis. N Engl J Med 2004, 350(21):2167-2169.
26. Edwards J.R., Sun S.G., Locklin R., Shipman C.M., Adamopoulos I.E., Athanasou N.A., et al. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis Rheum 2006, 54(5):1451-1462.
27. Kang Y.M., Kim S.Y., Kang J.H., Han S.W., Nam E.J., Kyung H.S., et al. LIGHT up-regulated on B lymphocytes and monocytes in rheumatoid arthritis mediates cellular adhesion and metalloproteinase production by synoviocytes. Arthritis Rheum 2007, 56(4):1106-1117.
28. Ishida S., Yamane S., Ochi T., Nakano S., Mori T., Juji T., et al. LIGHT induces cell proliferation and inflammatory responses of rheumatoid arthritis synovial fibroblasts via lymphotoxin beta receptor. J Rheumatol 2008, 35(6):960-968.
29. O'Rourke K.P., O'Donoghue G., Adams C., Mulcahy H., Molloy C., Silke C., et al. High levels of lymphotoxin-beta (LT-beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations. Rheumatol Int 2008, 28(10):979-986.
30. Young J., Yu X., Wolslegel K., Nguyen A., Kung C., Chiang E., et al. Lymphotoxin-αβ heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis. Cytokine 2010, 51(1):78-86.
31. Fava R.A., Notidis E., Hunt J., Szanya V., Ratcliffe N., Ngam-Ek A., et al. A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J Immunol 2003, 171(1):115-126.
32. Baldassare A., Fiechtner J., Filipowicz-Sosnowska A., Jeka S., O'Gorman J., Weaver M., et al. Preliminary safety and efficacy of LTβR-Ig (BG9924) in the treatment of rheumatoid arthritis (RA). Arthritis Rheum 2007, 56(Suppl. 9):S394. [abstract #947].
33. Genovese M.C., Greenwald M.W., Alloway J.A., Baldassare A.R., Chase W., Newman C., et al. Efficacy and safety of baminercept in the treatment of rheumatoid arthritis (RA) results of the phase 2B study in the TNF-IR population. Arthritis Rheum 2009, 60(Suppl. 10):417. [abstract].
34. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7(6):429-442.